Log in

Opinion

Emoluments clause and TrumpRX

OPINION — In September 2025, Forbes reported since Trump’s return to office, his net worth had nearly doubled. By the end of last year, some in Congress stated the actual increase was higher than $3 billion due to his bitcoin and cryptocurrency businesses.

However, these types of investments are notoriously hard to track, and this administration has only loosened and downsized watchdog regulations. What is known is that approximately 75% of the Trump crypto investors are from overseas. At a minimum, $1.5 billion as Trump’s increased net worth is a low estimate and disputed due to sudden resort deals in Qatar, Vietnam, UAE, etc. and gifts such as a $400 million 747 Boeing aircraft. All of these investments/gifts have occurred since the tariffs were announced.

Trump makes no pretense to avoid an emoluments conflict. In the latest AARP Bulletin magazine January 2026, page 5, the top headline reads foreseeable drug price cuts for the coming year. In that article it mentions the cost for popular GLP-1 drugs (used by 32 million Americans) will be lowered dramatically via a direct-to-consumer platform, TrumpRX, which is slated to launch in early 2026. This special platform will also be available through Medicare and Medicaid.

You must be a member to read this story.

Join our family of readers starting at $5 for your first month and support local, unbiased journalism.


Already have an account? Log in to continue.

Otherwise, follow the link below to join.

Please log in to continue

Log in